{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:01:52Z","timestamp":1785229312367,"version":"3.55.0"},"reference-count":59,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer (BC) can be treated by combinations of surgery, radiotherapy, chemotherapy, endocrine therapy and targeted therapies. High-risk patients, including all patients with axillary involved lymph nodes with triple-negative BC (TNBC) and Her2-positive BC, are treated by neoadjuvant chemotherapy (NAC). For high-risk patients, immunotherapy for TNBC, trastuzumab and pertuzumab then trastuzumab deruxtecan for Her2-positive BC have improved survival. In this narrative review, we will discuss therapy for small triple-negative and HER2-positive early BC without involved or suspicious axillary lymph nodes. Upfront surgery is recommended for cT1a-b cN0 usN0 TNBC and Her2-positive BC with adjuvant therapy for pT1b pN0 BC, discussed case by case for pT1a pN0 Her2-positive BC. No adjuvant chemotherapy is considered for pT1a TNBC. However, lymph vascular invasion can also be contributive on pathologic results. For pT1c pN0 TNBC and Her2-positive BC, adjuvant therapy is recommended. For cT2 or cN+ TNBC and Her2-positive BC, NAC is the treatment recommended with adjuvant therapy after surgery according to pathologic results. For cT1c cN0 usN0 TNBC and Her2-positive BC, upfront surgery is the usual treatment proposed but NAC can be strongly considered according to clinic pathologic characteristics, tumor size 10\u201315 mm or 16\u201320 mm, grade, young age (\u226435-years) and co-morbidities, particularly for elderly patients. Recent tools such as TIL level determined on core needle biopsy may help when considering NAC or upfront surgery and systemic therapy regimens. Other prognostic tools can contribute to the determined therapeutic strategy and systemic therapy regimens with escalation or de-escalation, such as TNBCDX or HER2DX, possibly in combination with TIL level.<\/jats:p>","DOI":"10.3390\/cancers18152422","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:55:41Z","timestamp":1785225341000},"page":"2422","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Small Triple-Negative and HER2-Positive Early Breast Cancer: Upfront Surgery or Neoadjuvant Chemotherapy?"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-6255","authenticated-orcid":false,"given":"Gilles","family":"Houvenaeghel","sequence":"first","affiliation":[{"name":"Department of Gynecology, Hopital Europ\u00e9en, 6 Rue D\u00e9sir\u00e9e Clary, 13003 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sabiani","sequence":"additional","affiliation":[{"name":"Department of Gynecology, H\u00f4pital de la Conception, AP-HM, 147 Bd Baille, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bouteille","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Centre Recherche Canc\u00e9rologie Marseille, Institution Paoli-Calmettes, 13009 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Quilichini","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Hopital Europ\u00e9en, 6 Rue D\u00e9sir\u00e9e Clary, 13003 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Cowen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, H\u00f4pital Europ\u00e9en, Institut Provence Radiotherapie Oncologie St\u00e9r\u00e9otaxie (IPROS), 6 Rue D\u00e9sir\u00e9e Clary, 13003 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Centre Recherche Canc\u00e9rologie Marseille, Institution Paoli-Calmettes, 13009 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Souquet Bressand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hopital Europ\u00e9en, 6 Rue D\u00e9sir\u00e9e Clary, 13003 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dumas, E., Laot, L., Coussy, F., Grandal Rejo, B., Daoud, E., Laas, E., Kassara, A., Majdling, A., Kabirian, R., and Jochum, F. (2022). The French Early Breast Cancer Cohort (FRESH): A Resource for Breast Cancer Research and Evaluations of Oncology Practices Based on the French National Healthcare System Database (SNDS). Cancers, 14.","DOI":"10.1101\/2022.03.14.22272286"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years\u2019 Follow-Up","volume":"39","author":"Piccart","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.23.02505","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis with Efficacy Update","volume":"42","author":"Loibl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): A randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Houvenaeghel, G., Lambaudie, E., Classe, J.M., Mazouni, C., Giard, S., Cohen, M., Faure, C., Charitansky, H., Rouzier, R., and Dara\u00ef, E. (2019). Lymph node positivity in different early breast carcinoma phenotypes: A predictive model. BMC Cancer, 19.","DOI":"10.1186\/s12885-018-5227-3"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10238-025-01591-5","article-title":"Predicting sentinel lymph node metastasis in breast cancer: A study based on the SEER database","volume":"25","author":"Li","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Reyal, F., Rouzier, R., Depont-Hazelzet, B., Bollet, M.A., Pierga, J.Y., Alran, S., Salmon, R.J., Fourchotte, V., Vincent-Salomon, A., and Sastre-Garau, X. (2011). The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020297"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/annonc\/mdt532","article-title":"Characteristics and clinical outcome of T1 breast cancer: A multicenter retrospective cohort study","volume":"25","author":"Houvenaeghel","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Chen, Y., Shen, H., Yan, S., Li, J., and Wu, W. (2024). Triple-negative breast cancer survival prediction: Population-based research using the SEER database and an external validation cohort. Front Oncol., 10.","DOI":"10.3389\/fonc.2024.1388869"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-007-9596-6","article-title":"Predicting features of breast cancer with gene expression patterns","volume":"108","author":"Lu","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3816\/CBC.2008.n.028","article-title":"Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer","volume":"8","author":"Crabb","year":"2008","journal-title":"Clin. Breast Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.humpath.2007.06.012","article-title":"Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers","volume":"39","author":"Liu","year":"2008","journal-title":"Hum. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-008-9914-7","article-title":"Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: Triple positive tumours are more likely lymph node positive","volume":"113","author":"Drijkoningen","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4143\/crt.2010.42.1.30","article-title":"Predictors of Axillary Lymph Node Metastases (ALNM) in a Korean Population with T1-2 Breast Carcinoma: Triple Negative Breast Cancer has a High Incidence of ALNM Irrespective of the Tumor Size","volume":"42","author":"Lee","year":"2010","journal-title":"Cancer Res. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.humpath.2006.04.015","article-title":"Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2\/neu-overexpressing phenotypes","volume":"37","author":"Kim","year":"2006","journal-title":"Hum. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Houvenaeghel, G., Cohen, M., Martino, M., Reyal, F., Classe, J.M., Chauvet, M.P., Colombo, P.E., Heinemann, M., Jouve, E., and Gimbergues, P. (2023). Negative Survival Impact of Occult Lymph Node Involvement in Small HER2-Positive Early Breast Cancer Treated by Up-Front Surgery. Cancers, 15.","DOI":"10.3390\/cancers15184567"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41523-021-00336-3","article-title":"Sentinel node involvement with or without completion axillary lymph node dissection: Treatment and pathologic results of randomized SERC trial","volume":"7","author":"Houvenaeghel","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/bjc.2016.283","article-title":"Axillary lymph node micrometastases decrease triple-negative early breast cancer survival","volume":"115","author":"Houvenaeghel","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103952","DOI":"10.1016\/j.critrevonc.2023.103952","article-title":"Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors: A systematic review and meta-analysis","volume":"184","author":"Hassing","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.14740\/wjon2578","article-title":"Adjuvant Therapy Benefits for Patients with Human Epidermal Growth Factor Receptor 2-Positive T1aN0M0 Breast Cancer: A Systematic Review and Meta-Analysis","volume":"16","author":"Ibrahim","year":"2025","journal-title":"World J. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105225","DOI":"10.1016\/j.critrevonc.2026.105225","article-title":"Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer\u2014A systematic review and meta-analysis","volume":"221","author":"Hassing","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clbc.2025.05.022","article-title":"Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis","volume":"25","author":"Wagner","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"oyae346","DOI":"10.1093\/oncolo\/oyae346","article-title":"Benefit of adjuvant chemotherapy for T1cN0M0 and selected T1bN0M0 triple-negative breast cancer: A nationwide cancer registry-based study Open Access","volume":"30","author":"Lo","year":"2025","journal-title":"Oncologist"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000546080","article-title":"St. Gallen\/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference","volume":"20","author":"Ditsch","year":"2025","journal-title":"Breast Care"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_30","unstructured":"(2025, October 22). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 5. [WWW Document]. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"St Gallen Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.20.02510","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Guideline Update","volume":"39","author":"Denduluri","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","unstructured":"(2021, November 09). National Comprehensive Cancer Network Clinical Practice Guidelines Oncology. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1419."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.3390\/curroncol31110484","article-title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting","volume":"31","author":"Manna","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100316","DOI":"10.1016\/j.esmoop.2021.100316","article-title":"Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study","volume":"6","author":"Houvenaeghel","year":"2021","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.26502\/jsr.10020251","article-title":"Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study","volume":"5","author":"Houvenaeghel","year":"2022","journal-title":"J. Surg. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","article-title":"Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers","volume":"176","author":"Houvenaeghel","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e6930","DOI":"10.1002\/cam4.6930","article-title":"Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival","volume":"13","author":"Houvenaeghel","year":"2024","journal-title":"Cancer Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.2005.03.3225","article-title":"Micrometastases in sentinel lymph node in a multicentric study: Predictive factors of nonsentinel lymph node involvement--Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer","volume":"24","author":"Houvenaeghel","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial","volume":"14","author":"Galimberti","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","article-title":"Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: Final results from the multicenter clinical trial AATRM 048\/13\/2000","volume":"20","author":"Alberro","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"znaf111","DOI":"10.1093\/bjs\/znaf111","article-title":"Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: Results from the prospective SENOMIC trial","volume":"112","author":"Andersson","year":"2025","journal-title":"Br. J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Houvenaeghel, G., El Hajj, H., Barrou, J., Cohen, M., Raro, P., De Troyer, J., Gimbergues, P., Tunon de Lara, C., Ceccato, V., and Vaini-Cowen, V. (2020). External Validation of the SERC Trial Population: Comparison with the Multicenter French Cohort, the Swedish and SENOMIC Trial Populations for Breast Cancer Patients with Sentinel Node Micro-Metastasis. Cancers, 12.","DOI":"10.3390\/cancers12102924"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","article-title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): An international, retrospective cohort study","volume":"27","author":"Montagna","year":"2026","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): The OPBC-05\/ICARO study","volume":"43","author":"Montagna","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jamaoncol.2024.1917","article-title":"Tumor-Infiltrating Lymphocytes in Patients with Stage I Triple-Negative Breast Cancer Untreated with Chemotherapy","volume":"10","author":"Geurts","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","volume":"331","author":"Jonas","year":"2024","journal-title":"JAMA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104120","DOI":"10.1016\/j.esmoop.2024.104120","article-title":"Tumor-infiltrating lymphocytes in HER2-positive breast cancer: Potential impact and challenges","volume":"10","author":"Schlam","year":"2025","journal-title":"ESMO Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e36810","DOI":"10.1097\/MD.0000000000036810","article-title":"Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis","volume":"103","author":"Xia","year":"2024","journal-title":"Medicine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2024.6872","article-title":"Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial","volume":"11","author":"Dieci","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"103801","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamaoncol.2023.7304","article-title":"Tumor intrinsic subtypes and gene expression signatures in early-stage ERBB2\/HER2-positive breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials","volume":"10","author":"Rediti","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(25)00276-1","article-title":"HER2DX and survival outcomes in early-stage HER2-positive breast cancer: An individual patient-level meta-analysis","volume":"26","author":"Villacampa","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Stecklein","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djaf162","article-title":"Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer","volume":"118","author":"Stecklein","year":"2026","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:09:48Z","timestamp":1785226188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":59,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152422"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152422","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}